AN OPEN LABEL PHASE II PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENT OF TREATMENT WITH CPX-351 (CYTARABINE: DAUNORUBICIN) LIPOSOME FOR INJECTION IN ACUTE LEUKEMIAS AND MDS PATIENTS WITH MODERATE HEPATIC IMPAIRMENT - Regional Cancer Care Associates LLC

Clinical Trials

AN OPEN LABEL PHASE II PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENT OF TREATMENT WITH CPX-351 (CYTARABINE: DAUNORUBICIN) LIPOSOME FOR INJECTION IN ACUTE LEUKEMIAS AND MDS PATIENTS WITH MODERATE HEPATIC IMPAIRMENT

Type of Cancer
Leukemia
Locations
Hackensack
Sponsor
Celator
Protocol Number
CLTR0314-208
Cancer Diagnosis
To Learn More Call
201-510-0910